These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 22761341

  • 1. FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.
    Buchbender C, Kuemmel S, Hoffmann O, Stahl AR, Kimmig R, Otterbach F, Ladd S, Koeninger A, Forsting M, Bockisch A, Antoch G, Heusner TA.
    Acta Radiol; 2012 Jul; 53(6):628-36. PubMed ID: 22761341
    [Abstract] [Full Text] [Related]

  • 2. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
    Luo J, Zhou Z, Yang Z, Chen X, Cheng J, Shao Z, Guo X, Tuan J, Fu X, Yu X.
    Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
    [Abstract] [Full Text] [Related]

  • 3. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J, Wang Y, Mo M, Bao X, Zhang Y, Liu G, Zhang J, Geng D.
    Oncotarget; 2015 Oct 06; 6(30):29388-95. PubMed ID: 26336821
    [Abstract] [Full Text] [Related]

  • 4. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
    Cheng X, Li Y, Liu B, Xu Z, Bao L, Wang J.
    Acta Radiol; 2012 Jul 06; 53(6):615-27. PubMed ID: 22734080
    [Abstract] [Full Text] [Related]

  • 5. A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.
    Kostakoglu L, Duan F, Idowu MO, Jolles PR, Bear HD, Muzi M, Cormack J, Muzi JP, Pryma DA, Specht JM, Hovanessian-Larsen L, Miliziano J, Mallett S, Shields AF, Mankoff DA, ACRIN 668 Investigative Team.
    J Nucl Med; 2015 Nov 06; 56(11):1681-9. PubMed ID: 26359256
    [Abstract] [Full Text] [Related]

  • 6. Early prediction of pathological complete response in luminal B type neoadjuvant chemotherapy-treated breast cancer patients: comparison between interim 18F-FDG PET/CT and MRI.
    Pahk K, Kim S, Choe JG.
    Nucl Med Commun; 2015 Sep 06; 36(9):887-91. PubMed ID: 25932536
    [Abstract] [Full Text] [Related]

  • 7. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Vallius T, Peter A, Auranen A, Carpén O, Kemppainen J, Matomäki J, Oksa S, Roering P, Seppänen M, Grénman S, Hynninen J.
    Gynecol Oncol; 2016 Jan 06; 140(1):29-35. PubMed ID: 26515076
    [Abstract] [Full Text] [Related]

  • 8. Role of 18F-PET/CT in Predicting Prognosis of Patients With Breast Cancer After Neoadjuvant Chemotherapy.
    Akimoto E, Kadoya T, Kajitani K, Emi A, Shigematsu H, Ohara M, Masumoto N, Okada M.
    Clin Breast Cancer; 2018 Feb 06; 18(1):45-52. PubMed ID: 28993056
    [Abstract] [Full Text] [Related]

  • 9. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
    Evangelista L, Cervino AR, Michieletto S, Saibene T, Orvieto E, Bozza F, Ghiotto C.
    Q J Nucl Med Mol Imaging; 2017 Jun 06; 61(2):205-215. PubMed ID: 25501326
    [Abstract] [Full Text] [Related]

  • 10. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
    Park JS, Moon WK, Lyou CY, Cho N, Kang KW, Chung JK.
    Acta Radiol; 2011 Feb 01; 52(1):21-8. PubMed ID: 21498321
    [Abstract] [Full Text] [Related]

  • 11. Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer.
    Zytoon AA, Murakami K, El-Kholy MR, El-Shorbagy E.
    Clin Radiol; 2008 Nov 01; 63(11):1213-27. PubMed ID: 18929039
    [Abstract] [Full Text] [Related]

  • 12. 18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer.
    Champion L, Lerebours F, Alberini JL, Fourme E, Gontier E, Bertrand F, Wartski M.
    J Nucl Med; 2015 Sep 01; 56(9):1315-21. PubMed ID: 26159587
    [Abstract] [Full Text] [Related]

  • 13. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
    Rossi C, Kanoun S, Berriolo-Riedinger A, Dygai-Cochet I, Humbert O, Legouge C, Chrétien ML, Bastie JN, Brunotte F, Casasnovas RO.
    J Nucl Med; 2014 Apr 01; 55(4):569-73. PubMed ID: 24566003
    [Abstract] [Full Text] [Related]

  • 14. The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
    Kumar A, Kumar R, Seenu V, Gupta SD, Chawla M, Malhotra A, Mehta SN.
    Eur Radiol; 2009 Jun 01; 19(6):1347-57. PubMed ID: 19214522
    [Abstract] [Full Text] [Related]

  • 15. The role of interim 18F-FDG PET/CT in predicting early response to neoadjuvant chemotherapy in breast cancer.
    Pahk K, Rhee S, Cho J, Seo M, Lee S, Park T, Park S, Lee E, Park KH, Kim C, Eo JS, Kim S, Choe JG.
    Anticancer Res; 2014 Aug 01; 34(8):4447-55. PubMed ID: 25075084
    [Abstract] [Full Text] [Related]

  • 16. Preoperative 18F-FDG PET/CT predicts disease-free survival in patients with primary invasive ductal breast cancer.
    Jo JE, Kim JY, Lee SH, Kim S, Kang T.
    Acta Radiol; 2015 Dec 01; 56(12):1463-70. PubMed ID: 25406431
    [Abstract] [Full Text] [Related]

  • 17. Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan.
    Suga K, Kawakami Y, Hiyama A, Matsunaga N.
    Ann Nucl Med; 2009 Jun 01; 23(4):399-407. PubMed ID: 19452249
    [Abstract] [Full Text] [Related]

  • 18. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
    Lee HW, Lee HM, Choi SE, Yoo H, Ahn SG, Lee MK, Jeong J, Jung WH.
    J Nucl Med; 2016 Aug 01; 57(8):1183-8. PubMed ID: 27033896
    [Abstract] [Full Text] [Related]

  • 19. Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer.
    Hatt M, Groheux D, Martineau A, Espié M, Hindié E, Giacchetti S, de Roquancourt A, Visvikis D, Cheze-Le Rest C.
    J Nucl Med; 2013 Mar 01; 54(3):341-9. PubMed ID: 23327900
    [Abstract] [Full Text] [Related]

  • 20. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
    Malik V, Lucey JA, Duffy GJ, Wilson L, McNamara L, Keogan M, Gillham C, Reynolds JV.
    J Nucl Med; 2010 Dec 01; 51(12):1863-9. PubMed ID: 21078796
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.